Tracon Pharmaceuticals (NASDAQ:TCON) stock is rocketing higher on Tuesday as investors react to a licensing agreement for its product development platform ( ).
According to a press release from the company, it has licensed this to a clinical-stage biotech company for an upfront payment of $3 million. This covers the design, conduct and administration of clinical trials, as well as research and development activities connected to them.
Charles Theuer, CEO of Tracon Pharmaceuticals, said the following about the licensing news:
“We are now in a position to widely license our PDP to allow clinical stage biotechnology and pharmaceutical companies to transform their clinical operations with the expectation of potentially dramatic cost reductions and shorter clinical trial timelines.”
TCON Stock Reactions on Tuesday
Following news of this agreement, shares of TCON stock are taking off with heavy trading. That has more than 23 million shares changing hands as of this writing. For the record, that’s well above its daily average trading volume of about 2.7 million shares.
TCON stock is up 18.8% as of Tuesday morning but was down 88% year-to-date (YTD) when markets closed on Monday.
Investors seeking out even more of the most recent stock market stories will want to stick around!
We’re offering coverage of all the latest stock market news for Tuesday! That includes a look at the biggest pre-market stock movers this morning, what’s happening with C3.ai (NYSE:AI) and more. All of that news is ready to go at the links below!
More Tuesday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- C3.ai Layoffs 2023: What to Know About the Latest AI Job Cuts
- Stock Market Crash Alert: What Credit Card Delinquencies Can Tell Us About 2024
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.